Jason Levy (Atlanta, USA) and Sandeep Bagla (Virginia, USA) talk to Interventional News about preliminary results from the ongoing OPuS One study. The OPuS One post market study is currently collecting real world data on the effectiveness of the OsteoCool radiofrequency ablation (RFA) system (Medtronic) for palliative treatment of spinal metastasis and benign bone tumours. The study is ongoing and continues to enrol patients globally.
This data was presented as an abstract at the SIR annual scientific meeting 2019.
Preliminary results for 34 patients treated with RF ablation with lesions in the thoracolumbar spine (predominately) and the pelvis and/or sacrum treated with OsteoCool have been analysed. The study investigators found in these preliminary data that patients exhibited rapid pain improvement at one week with 74% (25/34) patients experiencing significant change from baseline in worst pain of ≥2 points and sustained long-term relief through three months. Levy goes on to talk about the road being “wide open” for RFA therapy while Bagla outlines why the OPuS One study is so important to the field.
This video is sponsored by Medtronic.
Bagla S, Levy J, Hopkins T, et al. Abstract No. 618 Rapid pain improvement in patients treated for painful bone metastases with the Medtronic Osteocool RF Ablation system: the OPuS One study. J Vasc Intervent Radiol. 2019;30 (3 Supplement):S266-S267. doi:10.1016/j.jvir.2018.12.723.
